RayKnowChina Research Map
Shortlist

HangzhouZhejiang University School of Medicine

Fourth Affiliated Hospital of Zhejiang University

浙江大学医学院附属第四医院

Listed for 7 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Fourth Affiliated Hospital of Zhejiang University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌6 papers led
  2. Lung cancer肺癌9 papers led3 open trials led
  3. Osteosarcoma骨肉瘤0 papers led
  4. Coronary heart disease冠心病2 papers led
  5. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  6. IgA nephropathyIgA 肾病1 paper led
  7. Leber hereditary optic neuropathyLeber 遗传性视神经病变4 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 6 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 4420232024: 0020242025: 002025

7 hospitals in Hangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapy & targeted drugsHepatitis B & cirrhosisLocal treatment (ablation, TACE, HAIC)
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led6
  1. A Booster for Radiofrequency Ablation: Advanced Adjuvant Therapy via In Situ Nanovaccine Synergized with Anti-programmed Death Ligand 1 Immunotherapy for Systemically Constraining Hepatocellular Carcinoma.2023ACS nano
  2. Emerging biomolecules for practical theranostics of liver hepatocellular carcinoma.2023Annals of hepatology
  3. Cell Pair Algorithm-Based Immune Infiltrating Cell Signature for Improving Outcomes and Treatment Responses in Patients with Hepatocellular Carcinoma.2023CellsFree full text
  4. Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle.2023Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  5. Robust radiosensitization of hemoglobin-curcumin nanoparticles suppresses hypoxic hepatocellular carcinoma.2022Journal of nanobiotechnologyFree full text
  6. Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml.2021Frontiers in public healthFree full text
Chinese-language papers (not in the count)1
  1. [Clinical study on early predictors of concurrent bile duct injury following TACE in patients with liver cancer].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular CarcinomaActive, not recruitingNCT06966986Lead sponsorStart 2024-09

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 9 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.04%.

Papers led
9
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 6620232024: 1120242025: 112025

11 hospitals in Hangzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06458894

    Age 60 years to 99 years (registered criteria)

    Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou

  2. Recruiting
    Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
    Phase
    Not given
    Started
    2018-01
    Posted
    Registry
    NCT05636605

    Age 18 years to 80 years (registered criteria)

    Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou

  3. Not yet recruiting
    Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07545213

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Affiliated Hospital of Zhejiang UniversityHangzhou

  4. Not yet recruiting
    Video Double-Lumen Tube for Secondary Pulmonary Resection
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07467005

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led9
  1. Unraveling the immune mechanisms and therapeutic targets in lung adenosquamous transformation.2025Frontiers in immunologyFree full text
  2. Identification of ATAD3A as a key regulator in non-small cell lung cancer by promoting STAT3-induced cell proliferation and tumor angiogenesis.2024Molecular carcinogenesis
  3. Endobronchial ultrasound-guided transbronchial needle aspiration in peripheral pulmonary lesions: a systematic review and meta-analysis.2023Clinical & experimental metastasis
  4. Radionuclide-based theranostics - a promising strategy for lung cancer.2023European journal of nuclear medicine and molecular imagingFree full text
  5. Circulating insulin-like growth factor-1 and risk of lung diseases: A Mendelian randomization analysis.2023Frontiers in endocrinologyFree full text
  6. The Prognostic Value and Potential Mechanism of Tumor-Nutrition-Inflammation Index and Genes in Patients with Advanced Lung Cancer.2023International journal of clinical practiceFree full text
  7. Nanomedicine-based adjuvant therapy: a promising solution for lung cancer.2023Journal of nanobiotechnologyFree full text
  8. Metal Nanoparticles as Novel Agents for Lung Cancer Diagnosis and Therapy.2023Small (Weinheim an der Bergstrasse, Germany)
  9. Cost-effectiveness of Low-Dose Computed Tomography With a Plasma-Based Biomarker for Lung Cancer Screening in China.2022JAMA network openFree full text
Chinese-language papers (not in the count)1
  1. [Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].2023Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver MetastasisNot yet recruitingNCT07545213Lead sponsorPhase 2Start 2026-04
  2. Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.RecruitingNCT06458894Lead sponsorN/AStart 2024-08
  3. Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to ImmunotherapyRecruitingNCT05636605Lead sponsorStart 2018-01
  4. Study of Furmonertinib as Follow-Up Treatment After Surgery for Early-Stage EGFR-Positive Lung Cancer: Real-World ObservationActive, not recruitingNCT07940257Lead sponsorStart 2026-09
  5. Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerStatus unknownNCT05004974Lead sponsorPhase 2Start 2022-04
  6. Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small Cell Lung CancerActive, not recruitingNCT05636592Lead sponsorStart 2022-10
  7. Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC PatientsCompletedNCT04552613Lead sponsorN/AStart 2020-11
  8. Video Double-Lumen Tube for Secondary Pulmonary ResectionNot yet recruitingNCT07467005Study siteN/AStart 2026-03

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

20 hospitals in Hangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. Genetic Polymorphisms of Insulin-Like Growth Factor 1 Are Associated with Osteosarcoma Risk and Prognosis.2017Medical science monitor : international medical journal of experimental and clinical research

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 2 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.04%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

11 hospitals in Hangzhou for coronary heart disease231 hospitals in China for coronary heart disease

No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Hangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status1
  1. Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell TherapyNot yet recruitingNCT07359963Study siteEarly phase 1Start 2026-02

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

10 hospitals in Hangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Crescent calculator: A webtool enabling objective decision-making for assessment of IgA nephropathy immune activity throughout the disease course.2024Clinica chimica acta; international journal of clinical chemistry
All its trials on ClinicalTrials.gov, any status1
  1. Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA NephropathyCompletedNCT06460987Lead sponsorStart 2022-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 4 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 7.7%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 222025

5 hospitals in Hangzhou for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

浙江大学医学院附属第四医院

Fourth Affiliated Hospital of Zhejiang University

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data